1 - 2 of 2
1
Journal article icon

Journal article

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

  • Adams, R, Brown, E, Brown, L, et al.
  • 2017
2
Conference item icon

Conference item

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS

  • conference abstract
  • Adams, RA, Brown, E, Brown, L, et al.
  • 2016-10-11
FILTER RESULTS

TO TOP